The skin is one of the first and most obvious parts of the body to show signs of aging. It’s constantly exposed to everything the world throws at you, and over time, that leads to weathering, sagging, wrinkles, blemishes and all kinds of visible and textural changes. Skincare products are a big market, and now there may be a new therapy to rejuvenate tissue at the cellular level (https://longevity.technology/news/will-turn-bio-be-the-first-longevity-company-to-take-cell-rejuvenation-to-the-clinic/).
This new therapy comes from a company called Turn Biotechnologies, which specializes in using mRNA medicines to improve longevity by encouraging the body to heal itself. It’s not about just treating the symptoms of age-related conditions; it’s also about trying to cure the underlying disease. Areas researched by Turn Biotechnologies include osteoarthritis, cartilage damage, immunology, ophthalmology and musculature, but dermatology is right up at the top of the list.
TRN-001 is currently the most advanced therapy being developed by Turn Biotechnologies. It’s still in the preclinical stage, but the company recently had a positive meeting with FDA INTERACT about the treatment’s progress, including plans for its future advancement. CEO Anja Krammer described the “strong alignment” between Turn Bio’s position and the FDA’s response.
Messenger ribonucleic acid (mRNA) is essential to the body’s production of proteins. It has also become a significant part of modern medicine, particularly in the development of mRNA vaccines that treat conditions ranging from cancer to COVID-19. These therapies can be used to trigger an immune response while encouraging protein synthesis and restoring gene expression to its optimum performance.
In the context of TRN-001, the use of mRNA-based medicine works to repair and rejuvenate skin at the cellular level. It may reduce inflammation in addition to fixing damage, leading to overall improvements in the integrity of skin and a decrease in harmful senescent (sometimes called “zombie”) cells. This could even lead to a restoration of hair-growing ability for skin follicles.
Turn Bio uses a specially developed proprietary system of lipid particle carriers to deliver its mRNA medications, including TRN-001. This allows it to be effectively distributed through different tissues all around the body. There, it can restore and regenerate cells so they function at their best while combating disease and repairing damaged tissue.
No other company has managed to launch a skin rejuvenation therapy like TRN-001. If clinical trials are successful, it will be the first treatment of its kind.
